ZONEGRAN
What it isSodium- and calcium-channel-blocking antiepileptic with carbonic anhydrase inhibition; focal seizures.
Why this oneOnce-daily use and frequent weight loss distinguish it from many antiseizure drugs.
What limits itKidney stones and metabolic acidosis require attention; cognitive slowing, reduced sweating, and sulfonamide reactions can occur.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Partial seizures (adjunctive) | Adults ≥16 yr | 100 mg QD | 100-400 mg/day (QD or BID) | 600 mg/day |
Titration Increase no sooner than every 2 weeks (long half-life; up to 2 weeks to reach steady state)
Renal Use caution; may require slower titration and more frequent monitoring in renal disease
Hepatic Use caution; may require slower titration and more frequent monitoring in hepatic disease
Long half-life — allow ≥2 weeks at each dose level to reach steady state
Pregnancy May cause fetal harm — teratogenic in animals (cardiovascular malformations, embryolethality); can cause metabolic acidosis; monitor mother and neonate.
Lactation Undefined
NO BOXED WARNINGS
Principal riskKidney stones; sulfonamide cross-reactivity
Cost, est. cash$5–$150/month
Generic entry2005
Legacy pregnancy categoryC
Defining liabilityMetabolic acidosis, kidney stones, serious rash and reduced sweating/heat injury.

Open Zonisamide in the interactive console ↗


